Search Within

Tim Joseph Peterson

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (2)
Groups
  1. CTCR Scholars (8)
  2. Center for Hematologic Malignancies (8)
  3. Department of Medicine (8)
  4. Hematologic Malignancies Research (8)
  5. Hematologic Malignancies, Division of (8)
  6. Myeloma (8)

More Groups

People
  1. Alexander Lesokhin (8)
  2. Hani Hassoun (8)
  3. Malin Hultcrantz (8)
  4. Neha Korde (8)
  5. Sham Mailankody (8)
  6. Urvi Shah (8)

More People

Years
  1. 2022 (1)
  2. 2021 (2)
  3. 2020 (1)
  4. 2019 (4)
Publications
  1. Blood (5)
  2. British Journal of Haematology (1)
  3. Clinical Lymphoma, Myeloma and Leukemia (1)
  4. The Lancet Haematology (1)
Publishers
  1. American Society of Hematology (5)
  2. Elsevier Inc. (1)
  3. Elsevier Science, Inc. (1)
  4. John Wiley & Sons (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Journal Article

    Piedra, K.; Peterson, T.; Tan, C.; Orozco, J.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Lesokhin, A.; Shah, U.; Lu, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience
    Meeting Abstract

    Hultcrantz, M.; Orozco, J.; Peterson, T. J.; Derkach, A.; Hassoun, H.; Korde, N.; Lu, S. X.; Mailankody, S.; Patel, D.; Shah, U. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Practice patterns with focal progression on daratumumab therapy
    Meeting Abstract

    Bal, S.; Peterson, T.; Landau, H.; Chung, D.; Giralt, S.; Korde, N.; Mailankody, S.; Smith, E.; Shah, U.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save